000282585 001__ 282585
000282585 005__ 20251218105026.0
000282585 0247_ $$2doi$$a10.1093/brain/awaf339
000282585 0247_ $$2pmid$$apmid:40966722
000282585 0247_ $$2ISSN$$a0006-8950
000282585 0247_ $$2ISSN$$a1460-2156
000282585 037__ $$aDZNE-2025-01345
000282585 041__ $$aEnglish
000282585 082__ $$a610
000282585 1001_ $$aPescoller, Julia$$b0
000282585 245__ $$aCortical tau deposition promotes atrophy in connected white matter regions in Alzheimer's disease.
000282585 260__ $$aOxford$$bOxford Univ. Press$$c2025
000282585 3367_ $$2DRIVER$$aarticle
000282585 3367_ $$2DataCite$$aOutput Types/Journal article
000282585 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766051358_31262
000282585 3367_ $$2BibTeX$$aARTICLE
000282585 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282585 3367_ $$00$$2EndNote$$aJournal Article
000282585 520__ $$aIn Alzheimer's disease (AD), fibrillar tau pathology is a key driver of neurodegeneration and cortical atrophy. Yet, emerging evidence suggests that tau aggregates also contribute to white matter (WM) damage. Specifically, physiological tau stabilizes intra-axonal microtubules, whereas hyperphosphorylated tau disrupts microtubule integrity, with ensuing intraneuronal tau aggregation, neuronal disconnection and axonal degeneration. Therefore, we investigated whether cortical tau promotes atrophy in connected WM regions in AD. To this end, we included 186 amyloid-positive (Aβ+) patients across the AD spectrum and 102 cognitively normal (CN) amyloid-negative (Aβ-) participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) with baseline amyloid-PET, tau-PET and T1-weighted MRI. Longitudinal tau-PET and MRI (∼2 years) were available for a subset of 138 participants to assess the relationship between tau accumulation and WM atrophy over time. For replication, we included 378/60 CN Aβ+/Aβ- participants from the A4/LEARN cohort with baseline amyloid-PET, tau-PET and T1-weighted MRI, where a subset of 141/4 CN Aβ+/Aβ- subjects had ∼5-year longitudinal tau-PET and MRI. Cortical tau-PET standardized uptake value ratios were extracted from 210 cortical regions of the Brainnetome Atlas. In addition, we used a diffusion MRI-based tractography template to determine WM volumes of fibre tracts connected to cortical regions using segmented T1-weighted MRI. Using linear regression, we tested whether higher cortical tau-PET at baseline was associated with (i) lower baseline WM volume and (ii) faster WM volume loss over time, and (iii) whether faster longitudinal tau-PET increases paralleled faster WM loss. Testing the reverse model examined whether baseline WM atrophy predicted faster subsequent tau-PET increase in connected regions. Models were adjusted for age, sex, intracranial volume, WM hyperintensity volume, ApoE4 status and global amyloid-PET. In ADNI participants, elevated baseline cortical tau-PET in temporal regions was associated with lower baseline WM volume in adjacent regions, with more pronounced effects in patients across the AD spectrum and with weaker associations in the preclinical A4/LEARN sample. In both samples, higher baseline temporo-parietal tau-PET and faster tau-PET increase over time were significantly linked to accelerated volume loss in connected WM regions, which was especially pronounced in individuals on the AD spectrum. Importantly, baseline WM volume did not predict subsequent tau-PET rates of change in adjacent cortical regions, suggesting a unidirectional relationship between fibrillar tau and subsequent WM degeneration. Together, our findings suggest that cortical tau accumulation promotes atrophy in adjacent WM regions in AD, highlighting that tau-induced axonal degeneration and, potentially, neuronal disconnection might play a pivotal role in disease progression.
000282585 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282585 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000282585 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282585 650_7 $$2Other$$aAlzheimer’s disease
000282585 650_7 $$2Other$$aneuroimaging
000282585 650_7 $$2Other$$aprogressive white matter degeneration
000282585 650_7 $$2Other$$atau pathology
000282585 650_7 $$2NLM Chemicals$$atau Proteins
000282585 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000282585 650_7 $$2NLM Chemicals$$aMAPT protein, human
000282585 650_2 $$2MeSH$$aHumans
000282585 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000282585 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000282585 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000282585 650_2 $$2MeSH$$atau Proteins: metabolism
000282585 650_2 $$2MeSH$$aMale
000282585 650_2 $$2MeSH$$aFemale
000282585 650_2 $$2MeSH$$aAged
000282585 650_2 $$2MeSH$$aWhite Matter: pathology
000282585 650_2 $$2MeSH$$aWhite Matter: metabolism
000282585 650_2 $$2MeSH$$aWhite Matter: diagnostic imaging
000282585 650_2 $$2MeSH$$aAtrophy: pathology
000282585 650_2 $$2MeSH$$aAtrophy: metabolism
000282585 650_2 $$2MeSH$$aPositron-Emission Tomography
000282585 650_2 $$2MeSH$$aAged, 80 and over
000282585 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000282585 650_2 $$2MeSH$$aCerebral Cortex: pathology
000282585 650_2 $$2MeSH$$aCerebral Cortex: metabolism
000282585 650_2 $$2MeSH$$aCerebral Cortex: diagnostic imaging
000282585 650_2 $$2MeSH$$aMiddle Aged
000282585 650_2 $$2MeSH$$aLongitudinal Studies
000282585 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000282585 7001_ $$00000-0002-5636-196X$$aDewenter, Anna$$b1
000282585 7001_ $$aDehsarvi, Amir$$b2
000282585 7001_ $$aSteward, Anna$$b3
000282585 7001_ $$00000-0001-9321-956X$$aFrontzkowski, Lukas$$b4
000282585 7001_ $$aZhu, Zeyu$$b5
000282585 7001_ $$00000-0003-3423-457X$$aRoemer-Cassiano, Sebastian N$$b6
000282585 7001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b7
000282585 7001_ $$aHirsch, Fabian$$b8
000282585 7001_ $$aWagner, Fabian$$b9
000282585 7001_ $$00000-0002-9011-1120$$ade Bruin, Hannah$$b10
000282585 7001_ $$0P:(DE-2719)9001808$$aRauchmann, Boris Stephan$$b11$$udzne
000282585 7001_ $$0P:(DE-2719)2812234$$aPerneczky, Robert$$b12$$udzne
000282585 7001_ $$0P:(DE-2719)9001652$$aGnoerich, Johannes$$b13$$udzne
000282585 7001_ $$00000-0001-8923-9656$$aMalpetti, Maura$$b14
000282585 7001_ $$aOssenkoppele, Rik$$b15
000282585 7001_ $$00000-0001-7800-1781$$aSchöll, Michael$$b16
000282585 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b17
000282585 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b18$$udzne
000282585 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b19
000282585 7001_ $$00000-0001-9736-2283$$aFranzmeier, Nicolai$$b20
000282585 773__ $$0PERI:(DE-600)1474117-9$$a10.1093/brain/awaf339$$gVol. 148, no. 12, p. 4359 - 4371$$n12$$p4359 - 4371$$tBrain$$v148$$x0006-8950$$y2025
000282585 8564_ $$uhttps://pub.dzne.de/record/282585/files/DZNE-2025-01345%20SUP.zip
000282585 8564_ $$uhttps://pub.dzne.de/record/282585/files/DZNE-2025-01345_Restricted.pdf
000282585 8564_ $$uhttps://pub.dzne.de/record/282585/files/DZNE-2025-01345_Restricted.pdf?subformat=pdfa$$xpdfa
000282585 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000852$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000282585 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001808$$aExternal Institute$$b11$$kExtern
000282585 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812234$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000282585 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001652$$aExternal Institute$$b13$$kExtern
000282585 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b17$$kDZNE
000282585 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b18$$kDZNE
000282585 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b19$$kDZNE
000282585 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282585 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000282585 9141_ $$y2025
000282585 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-12$$wger
000282585 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN : 2022$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-12
000282585 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bBRAIN : 2022$$d2024-12-12
000282585 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000282585 9201_ $$0I:(DE-2719)5000022$$kAG Dichgans$$lVascular Cognitive Impairment & Post-Stroke Dementia$$x1
000282585 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x2
000282585 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x3
000282585 980__ $$ajournal
000282585 980__ $$aVDB
000282585 980__ $$aI:(DE-2719)1111015
000282585 980__ $$aI:(DE-2719)5000022
000282585 980__ $$aI:(DE-2719)1111016
000282585 980__ $$aI:(DE-2719)1110007
000282585 980__ $$aUNRESTRICTED